# CG Oncology, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/CG Oncology, Inc.). ## Overview CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. Its lead program is designed to both directly kill cancer cells and stimulate an anti-tumor immune response, with the initial focus on high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). The company is still in development mode and does not yet sell an approved product, so its value proposition is tied primarily to clinical success, regulatory approval, and eventual commercialization. In addition to its core drug program, CG Oncology has built in-house chemistry, manufacturing and controls capabilities and commercial-readiness infrastructure to support a potential launch. The company also has a commercial and development revenue stream through Biovire, a contract manufacturing business focused on fill-and-finish services for novel drugs and medical devices. ## Products & services • Cretostimogene grenadenorepvec for bladder cancer • Oncolytic immunotherapy clinical development • Non-muscle invasive bladder cancer (NMIBC) programs • CMC and manufacturing development capabilities • Biovire fill-and-finish contract manufacturing services - **Lead oncology drug candidate** (0%) — Development of cretostimogene grenadenorepvec as a potential therapy for bladder cancer, especially NMIBC. - **Clinical development services** (0%) — Preclinical and clinical trial activities supporting the advancement of the lead program. - **Manufacturing and CMC capabilities** (0%) — Internal process development, analytical development, and virus-related manufacturing support. - **License and collaboration revenue** (100%) — Revenue recognized from licensing and collaboration agreements while the product remains in development. - **Commercial and development revenue** (0%) — Biovire fill-and-finish services for novel drugs and medical devices. - Cretostimogene grenadenorepvec for bladder cancer - Oncolytic immunotherapy clinical development - Non-muscle invasive bladder cancer (NMIBC) programs - CMC and manufacturing development capabilities - Biovire fill-and-finish contract manufacturing services ## Customers CG Oncology’s primary end customers are patients with high-risk and intermediate-risk NMIBC, but the company’s near-term economic counterparties are pharmaceutical collaborators, license partners, and healthcare providers involved in clinical trials. If cretostimogene is approved, the commercial customer base would expand to urologists, oncology centers, and hospitals treating bladder cancer patients. In the meantime, the company also serves biopharma customers through Biovire’s fill-and-finish manufacturing services for novel drugs and medical devices. The company’s collaboration revenue depends on partners that value access to its technology, intellectual property, and development capabilities. Demand in the eventual commercial market will be driven by clinical efficacy, tolerability, convenience, and the ability to compete against BCG and other NMIBC therapies. - **Bladder cancer patients** (primary) — Patients with high-risk or intermediate-risk NMIBC are the intended therapeutic population for cretostimogene because they need effective bladder-sparing treatment options. - **Urology and oncology treatment centers** (primary) — Hospitals, clinics, and physicians would administer the therapy and determine adoption based on safety, efficacy, and convenience. - **Pharmaceutical collaboration partners** (secondary) — Partners license or collaborate on the platform to gain access to the drug candidate, development know-how, or commercialization rights. - **Biopharma manufacturing customers** (secondary) — Customers of Biovire buy fill-and-finish services for novel drugs and medical devices, creating non-product revenue. - **Clinical investigators and trial sites** (secondary) — These stakeholders support enrollment and execution of clinical studies needed to generate regulatory evidence. - Bladder cancer patients who would receive cretostimogene if approved - Urologists and oncology centers that would prescribe/administer the therapy - Pharmaceutical collaborators that license or co-develop the platform - Biopharma customers using Biovire fill-and-finish services - Clinical trial sites and investigators supporting patient enrollment - Payers and health systems that will influence adoption after approval ## Geography CG Oncology is headquartered in the United States and its business is currently centered on U.S.-based clinical development, regulatory engagement, and commercial preparation. The company’s lead indication, NMIBC, is a U.S. and global oncology market, but the filings emphasize U.S. patient estimates and U.S.-centric development activities. The company also notes exposure to foreign jurisdictions through regulation, litigation, supply chain, and potential future commercialization, even though no country-level revenue disclosure is provided. Because the company is still pre-commercial for its lead drug, geography matters more through trial execution, regulatory pathways, and manufacturing/supply-chain resilience than through current sales mix. Biovire and future collaboration activity could broaden the operating footprint over time, but the disclosed revenue base is not broken out by country. - Headquartered in the United States - Clinical and regulatory activity is primarily U.S.-based - Target market for NMIBC is described using U.S. patient estimates - Foreign jurisdictions matter mainly for regulation, supply chain, and legal exposure - No country-level revenue disclosure was provided in the excerpts ## Strategy CG Oncology’s strategy is to advance cretostimogene through late-stage development and position it as a backbone therapy in bladder cancer, starting with NMIBC. The company is also building commercial infrastructure ahead of a potential FDA approval, which is important because it has no prior product-launch experience. A second strategic pillar is maintaining strong CMC and manufacturing capabilities so it can support clinical supply and future commercialization without relying entirely on third parties. The company also expects to fund operations through existing cash, future equity or debt, and collaboration/licensing arrangements until product revenue is possible. Biovire adds a complementary revenue stream and manufacturing capability that can support both operations and strategic flexibility. - **Complete clinical development of cretostimogene** (short-term) — The company depends on a single lead asset, so clinical success is the main driver of future value and commercialization potential. - **Prepare for commercial launch** (short-term) — The company has no commercial product history, so building sales, marketing, and market access capabilities is necessary to convert approval into revenue. - **Secure non-product funding and partnerships** (short-term) — Until product sales begin, the company must rely on capital markets and collaboration income to fund operations. - **Strengthen manufacturing and CMC execution** (medium-term) — Reliable clinical and future commercial supply is critical for a biologic/oncolytic therapy and can be a differentiator in regulatory review and launch readiness. - Advance cretostimogene through clinical development toward FDA approval - Target high-risk and intermediate-risk NMIBC as the initial commercial indication - Build commercial readiness before launch to reduce execution risk - Strengthen in-house CMC and manufacturing capabilities for supply control - Use collaborations and licenses to fund development before product sales begin - Leverage Biovire to add manufacturing revenue and operational capability ## Risks CG Oncology is highly exposed to clinical, regulatory, and commercialization risk because it depends entirely on cretostimogene, its only product candidate. If the program fails, is delayed, or does not achieve approval, the company may never generate product revenue and could need to raise capital on unfavorable terms. The competitive environment is intense, with BCG and multiple larger pharmaceutical and biotechnology companies pursuing NMIBC therapies that may be safer, more effective, or faster to market. As a development-stage biopharma company, it also faces manufacturing, trial execution, intellectual property, and reimbursement risk, all of which can materially affect adoption even if approval is obtained. Broader risks include litigation, government investigations, supply-chain disruption, pandemics, and macroeconomic or tariff-related pressure that can raise costs and slow clinical operations. - **Dependence on a single product candidate** [critical] — The company currently depends entirely on cretostimogene, so any setback in development or approval would materially harm the business. - **Clinical and regulatory failure** [critical] — The company has no approved products, so it cannot generate product revenue unless trials succeed and regulators approve the therapy. - **Competitive pressure in NMIBC** [high] — Established and emerging competitors may reach market first or offer better efficacy, safety, or convenience than cretostimogene. - **Financing risk** [high] — The company expects to need substantial additional funding before product sales are possible, and capital may not be available on favorable terms. - **Manufacturing and supply-chain risk** [high] — Clinical and future commercial supply depends on complex biologic manufacturing and third-party logistics that can be disrupted. - **Litigation and regulatory enforcement** [medium] — Operating in a highly regulated industry creates exposure to IP, product liability, privacy, anti-kickback, and other claims. - Single-asset dependence on cretostimogene - Clinical trial failure or delay could eliminate the core value driver - Regulatory approval risk for a late-stage biologic therapy - Competition from BCG and larger NMIBC developers - Need for substantial future capital before product sales begin - Manufacturing and supply-chain disruption risk for clinical and commercial supply - Litigation, compliance, and government investigation exposure ## Accounting The most important accounting issue for CG Oncology is revenue recognition, because current revenue comes from license and collaboration arrangements and from Biovire’s commercial and development services rather than from product sales. The company has disclosed that it has recognized license and collaboration revenue over time through its agreements, while product sales of cretostimogene have not yet begun and are not expected in the foreseeable future. R&D expense recognition is also critical because substantially all development costs are expensed as incurred, making reported losses sensitive to trial activity, manufacturing spend, and headcount. The company also holds marketable securities and has made investment-related transactions, so fair value and classification judgments can affect the balance sheet and cash flow presentation. In addition, estimates for accrued R&D, prepaid expenses, and stock-based compensation can materially affect quarterly comparability in a pre-revenue biotech model. - **License and collaboration revenue recognition** — Can create uneven revenue recognition across periods. - **R&D expense accruals** — Can materially change reported operating loss in a quarter. - **Fair value of marketable securities** — Affects balance sheet liquidity presentation and non-operating results. - **Stock-based compensation** — Can distort comparability across periods if grant activity changes. - License and collaboration revenue recognition affects reported top-line timing - Biovire service revenue depends on contract accounting and delivery of fill-and-finish services - R&D is expensed as incurred, so clinical activity drives operating losses - Accrued R&D and prepaid balances require judgment and can shift quarterly expense timing - Marketable securities and other investments require fair value and classification judgments - Stock-based compensation can materially affect operating expense in a pre-revenue company --- *Last updated: 2026-08-11T04:46:25.794240+00:00*